Global Inavolisib Tablets Market Strategic Research Report

Scope of the Report

The global Inavolisib Tablets market size is predicted to grow from US$ 162 million in 2025 to US$ 957 million in 2032; it is expected to grow at a CAGR of 23.9% from 2026 to 2032.

Inavolisib is an orally administered small-molecule selective inhibitor of PI3Kα (phosphatidylinositol 3-kinase alpha isoform). It is primarily used for the treatment of patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced or metastatic breast cancer. The drug exerts its anti-tumor effects by selectively inhibiting the PI3K/AKT/mTOR signaling pathway, thereby blocking tumor cell proliferation and survival signals.

Inavolisib is typically used in combination with endocrine therapy and CDK4/6 inhibitors. It has significant clinical value in delaying disease progression and improving patient outcomes, and represents a new generation of advances in PI3K-targeted therapy.In 2025, global Inavolisib production reached approximately 30,000 bottles.

Inavolisib, as a new-generation PI3Kα-selective inhibitor, holds significant development potential in the treatment market for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced or metastatic breast cancer with PIK3CA mutations. With the continuous rise in global breast cancer incidence and the increasing penetration of precision molecular diagnostics—particularly PIK3CA testing—the PI3K pathway-targeted therapy market is gradually expanding.

Compared with first-generation PI3K inhibitors, Inavolisib demonstrates improved selectivity, safety, and potential in combination therapy with CDK4/6 inhibitors, which may enhance its clinical utilization. From a competitive landscape perspective, the field already includes established products such as alpelisib. However, Inavolisib is expected to achieve differentiated competition in the future due to its superior clinical data and combination treatment strategies.

Looking ahead, with ongoing global regulatory approvals, standardization of combination therapy regimens, and expansion of reimbursement coverage, its market size is expected to grow rapidly, securing an important position in the HR+/HER2− breast cancer precision therapy landscape.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Inavolisib Tablets market?

What factors are driving Inavolisib Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Inavolisib Tablets market opportunities vary by end market size?

How does Inavolisib Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Inavolisib Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 5 mg
• 10 mg

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Route of Administration

• Oral Administration
• Intravenous Administration, IV

Segment by Dosage Forms

• Tablet
• Capsule

Segment by Application

• HR+/HER2- Advanced or Metastatic Breast Cancer
• PIK3CA-Mutated Tumor Targeted Therapy
• Combination Therapy Applications
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Inavolisib Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in HR+/HER2- Advanced or Metastatic Breast Cancer, PIK3CA-Mutated Tumor Targeted Therapy, Combination Therapy Applications evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact